ISSN 1671-5411 CN 11-5329/R
Volume 18 Issue 3
Mar.  2021
Turn off MathJax
Article Contents
Please cite this article as: Díez-Villanueva P, Jiménez-Méndez C, Alfonso F. Heart failure in the elderly. J Geriatr Cardiol 2021; 18(3): 219−232. DOI: 10.11909/j.issn.1671-5411.2021.03.009
Citation: Please cite this article as: Díez-Villanueva P, Jiménez-Méndez C, Alfonso F. Heart failure in the elderly. J Geriatr Cardiol 2021; 18(3): 219−232. DOI: 10.11909/j.issn.1671-5411.2021.03.009

Heart failure in the elderly

doi: 10.11909/j.issn.1671-5411.2021.03.009
More Information
  • Corresponding author: falf@hotmail.com
  • Available Online: 2021-03-28
  • Publish Date: 2021-03-31
  • Heart failure (HF) is a clinical syndrome caused by structural and/or functional cardiac abnormalities, resulting in a reduced cardiac output and/or elevated intracardiac filling pressures at rest or during stress. HF is a major public health problem with high prevalence and incidence, involving both high morbidity and mortality, but also high economic costs. The incidence of HF progressively increases with age, reaching around 20% among people over 75 years old. Indeed, HF represents the leading cause of hospitalization in patients older than 65 years in Western countries. Hence, some authors even consider HF a geriatric syndrome, entailing worse prognosis and high residual disability, and often associating some complex comorbidities, common in older population, that may further complicate the course of the disease. On the other hand, however, clinical course and prognosis may be often difficult to predict. In this article, main pathophysiological issues related to the aging heart are addressed, together with key aspects related to both diagnosis and prognosis in elderly patients with HF. Besides, main geriatric conditions, common in the elderly population, are reviewed, highlighting the importance of a comprehensive and multidisciplinary approach.
  • *The authors contributed equally to this manuscript
  • loading
  • [1]
    Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur J Heart Fail 2016; 18: 891−975. doi: 10.1002/ejhf.592
    [2]
    Ho KK, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 1993; 22(4 Suppl A): 6A−13A.
    [3]
    Díez-Villanueva P, Alfonso F. Heart failure in the elderly. J Geriatr Cardiol 2016; 13: 115−117.
    [4]
    Petrie MC, Berry C, Stewart S, et al. Failing aging hearts. Eur Heart J 2001; 22: 1978−1990. doi: 10.1053/euhj.2000.2558
    [5]
    Martín-Sánchez FJ, Christ M, Miró Ò, et al. Practical approach on frail older patients attended for acute heart failure. Int J Cardiol 2016; 222: 62−71. doi: 10.1016/j.ijcard.2016.07.151
    [6]
    Filippatos G, Parissis JT. Heart failure diagnosis and prognosis in the elderly: the proof of the pudding is in the eating. Eur J Heart Fail 2011; 13: 467−471. doi: 10.1093/eurjhf/hfr036
    [7]
    García Pinilla JM, Díez-Villanueva P, Bover Freire R, et al. Consensus document and recommendations on palliative care in heart failure of the Heart Failure and Geriatric Cardiology Working Groups of the Spanish Society of Cardiology. Rev Esp Cardiol 2020; 73: 69−77. doi: 10.1016/j.recesp.2019.06.024
    [8]
    Sobanski PZ, Alt-Epping B, Currow DC, et al. Palliative care for people living with heart failure: European Association for Palliative Care Task Force expert position statement. Cardiovasc Res 2020; 116: 12−27. doi: 10.1093/cvr/cvz200
    [9]
    Zakeri R, Cowie MR. Heart failure with preserved ejection fraction: controversies, challenges and future directions. Heart 2018; 104: 377−384. doi: 10.1136/heartjnl-2016-310790
    [10]
    Shah SJ, Kitzman DW, Borlaug BA, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation 2016; 134: 73−90. doi: 10.1161/CIRCULATIONAHA.116.021884
    [11]
    Triposkiadis F, Xanthopoulos A, Butler J. Cardiovascular aging and heart failure. J Am Coll Cardiol 2019; 74: 804−813. doi: 10.1016/j.jacc.2019.06.053
    [12]
    Steenman M, Lande G. Cardiac aging and heart disease in humans. Biophys Rev 2017; 9: 131−137. doi: 10.1007/s12551-017-0255-9
    [13]
    Sanada F, Taniyama Y, Muratsu J, et al. Source of chronic inflammation in aging. Front Cardiovasc Med 2018; 5: 12. doi: 10.3389/fcvm.2018.00012
    [14]
    Lazar E, Sadek HA, Bergmann O. Cardiomyocyte renewal in the human heart: insights from the fall-out. Eur Heart J 2017; 38: 2333−2342. doi: 10.1093/eurheartj/ehx343
    [15]
    Díez-Villanueva P, Jiménez-Méndez C, Alfonso F. Non-ST elevation acute coronary syndrome in the elderly. J Geriatr Cardiol 2020; 17: 9−15.
    [16]
    Abdelhafz AH. Heart failure in older people: causes, diagnosis and treatment. Age Ageing 2002; 31: 29−36.
    [17]
    Berliner D, Bauersachs J. Drug treatment of heart failure in the elderly. Herz 2018; 43: 207−213. doi: 10.1007/s00059-017-4668-9
    [18]
    Luchner A, Behrens G, Stritzke J, et al. Long-term pattern of brain natriuretic peptide and N-terminal pro brain natriuretic peptide and its determinants in the general population: contribution of age, gender, and cardiac and extra-cardiac factors. Eur J Heart Fail 2013; 15: 859−867. doi: 10.1093/eurjhf/hft048
    [19]
    Plichart M, Orvoën G, Jourdain P, et al. Brain natriuretic peptide usefulness in very elderly dyspnoeic patients: the BED study. Eur J Heart Fail 2017; 19: 540−548. doi: 10.1002/ejhf.699
    [20]
    Sanders-van Wijk S, Muzzarelli S, Neuhaus M, et al. Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF. Eur J Heart Fail 2013; 15: 910−918. doi: 10.1093/eurjhf/hft079
    [21]
    Komajda M, Hanon O, Hochadel M, et al. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J 2009; 30: 478−486.
    [22]
    Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol 2020; 17: 559−573. doi: 10.1038/s41569-020-0363-2
    [23]
    Reddy YNV, Carter RE, Obokata M, et al. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 2018; 138: 861−870. doi: 10.1161/CIRCULATIONAHA.118.034646
    [24]
    Metra M, Cotter G, El-Khorazaty J, et al. Acute heart failure in the elderly: differences in clinical characteristics, outcomes, and prognostic factors in the VERITAS Study. J Card Fail 2015; 21: 179−188. doi: 10.1016/j.cardfail.2014.12.012
    [25]
    Metra M, Mentz RJ, Chiswell K, et al. Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial. Eur J Heart Fail 2015; 17: 109−118. doi: 10.1002/ejhf.207
    [26]
    González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015; 36: 2585−2594. doi: 10.1093/eurheartj/ehv338
    [27]
    Garcia-Pavia P, Domínguez F, Gonzalez-Lopez E. Transthyretin amyloid cardiomyopathy. Med Clin (Barc) 2021; 156: 126−134. doi: 10.1016/j.medcli.2020.06.064
    [28]
    Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: evolving diagnosis and management. AHA scientific statement. Circulation 2020; 142: e7−e22. doi: 10.1161/CIRCULATIONAHA.120.047293
    [29]
    Cherubini A, Oristrell J, Pla X, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med 2011; 171: 550−556.
    [30]
    Afilalo J. Evaluating and treating frailty in cardiac rehabilitation. Clin Geriatr Med 2019; 35: 445−457. doi: 10.1016/j.cger.2019.07.002
    [31]
    Busch JC, Lillou D, Wittig G, et al. Resistance and balance training improves functional capacity in very old participants attending cardiac rehabilitation after coronary bypass surgery. J Am Geriatr Soc 2012; 60: 2270−2276. doi: 10.1111/jgs.12030
    [32]
    Suaya JA, Stason WB, Ades PA, et al. Cardiac rehabilitation and survival in older coronary patients. J Am Coll Cardiol 2009; 54: 25−33. doi: 10.1016/j.jacc.2009.01.078
    [33]
    Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37: 2315−2381. doi: 10.1093/eurheartj/ehw106
    [34]
    Writing Committee. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2021; 77: 772−810. doi: 10.1016/j.jacc.2020.11.022
    [35]
    McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993−1004. doi: 10.1056/NEJMoa1409077
    [36]
    Jhund PS, Fu M, Bayram E, et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J 2015; 36: 2576−2784. doi: 10.1093/eurheartj/ehv330
    [37]
    Esteban-Fernández A, Díez-Villanueva P, Vicent L, et al. Sacubitril/Valsartan is useful and safe in elderly people with heart failure and reduced ejection fraction. Data from a real-word cohort. Rev Esp Geriatr Gerontol 2020; 55: 65−69. doi: 10.1016/j.regg.2019.10.002
    [38]
    Díez-Villanueva P, Vicent L, de la Cuerda F, et al. Left Ventricular Ejection Fraction Recovery in Patients with Heart Failure and Reduced Ejection Fraction Treated with Sacubitril/Valsartan. Cardiology 2020; 145: 275−282. doi: 10.1159/000505148
    [39]
    Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338−2345. doi: 10.1093/eurheartj/ehl250
    [40]
    CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429−1435. doi: 10.1056/NEJM198706043162301
    [41]
    Barywani SB, Ergatoudes C, Schaufelberger M, et al. Does the target dose of neurohormonal blockade matter for outcome in systolic heart failure in octogenarians? Int J Cardiol 2015; 187: 666−672. doi: 10.1016/j.ijcard.2015.03.428
    [42]
    Cohen-Solal A, McMurray JJ, Swedberg K, et al. CHARM Investigators. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure-Assessment of Reduction in Mortality and Morbidity Programme. Eur Heart J 2008; 29: 3022−3028. doi: 10.1093/eurheartj/ehn476
    [43]
    Baruch L, Glazer RD, Aknay N, et al. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2004; 148: 951−957. doi: 10.1016/j.ahj.2004.06.001
    [44]
    Kotecha D, Manzano L, Krum H, et al. Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ 2016; 353: i1855.
    [45]
    Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215−225. doi: 10.1093/eurheartj/ehi115
    [46]
    Ambrosio G, Flather MD, Böhm M, et al. B-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure. Heart 2011; 97: 209−214. doi: 10.1136/hrt.2010.207365
    [47]
    Japp D, Shah A, Fisken S, et al. Mineralocorticoid receptor antagonists in elderly patients with heart failure: a systematic review and meta-analysis. Age Ageing 2017; 46: 18−25.
    [48]
    Ferreira J, Rossello X, Eschalier R, et al. MRAs in elderly HF patients. JACC Heart Fail 2019: 1012−1021.
    [49]
    Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393: 31−39. doi: 10.1016/S0140-6736(18)32590-X
    [50]
    Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 2020; 396: 819−829. doi: 10.1016/S0140-6736(20)31824-9
    [51]
    Martinez FA, Serenelli M, Nicolau JC, et al. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation 2020; 141: 100−111. doi: 10.1161/CIRCULATIONAHA.119.044133
    [52]
    Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet 2020; 396: 121−128. doi: 10.1016/S0140-6736(20)30748-0
    [53]
    Muntwyler J, Cohen-Solal A, Freemantle N, et al. Relation of sex, age and concomitant diseases to drug prescription for heart failure in primary care in Europe. Eur J Heart Fail 2004; 6: 663−668. doi: 10.1016/j.ejheart.2004.03.011
    [54]
    Akita K, Kohno T, Kohsaka S, et al. Current use of guideline-based medical therapy in elderly patients admitted with acute heart failure with reduced ejection fraction and its impact on event-free survival. Int J Cardiol 2017; 235: 162−168. doi: 10.1016/j.ijcard.2017.02.070
    [55]
    Rutten FH, Grobbee DE, Hoes AW. Differences between general practitioners and cardiologists in diagnosis and management of heart failure: a survey in every-day practice. Eur J Heart Fail 2003; 5: 337−344. doi: 10.1016/S1388-9842(03)00050-3
    [56]
    Rich MW. Pharmacotherapy of heart failure in the elderly: adverse events. Heart Fail Rev 2012; 17: 589−595. doi: 10.1007/s10741-011-9263-1
    [57]
    Rich MW, McSherry F, Williford WO, et al. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol 2001; 38: 806−813. doi: 10.1016/S0735-1097(01)01442-5
    [58]
    Tavazzi L, Swedberg K, Komajda M, et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: Insights from the SHIFT study. Eur J Heart Fail 2013; 15: 1296−1303. doi: 10.1093/eurjhf/hft102
    [59]
    Lip GYH, Ponikowski P, Andreotti F, et al. Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Eur J Heart Fail 2012; 14: 681−695. doi: 10.1093/eurjhf/hfs073
    [60]
    Westenbrink B, De Boer R, Voors A, et al. Anemia in chronic heart failure: Etiology and treatment options. Curr Opin Cardiol 2008; 23: 141−147. doi: 10.1097/HCO.0b013e3282f43025
    [61]
    Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436−2448. doi: 10.1056/NEJMoa0908355
    [62]
    Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015; 36: 657−668. doi: 10.1093/eurheartj/ehu385
    [63]
    Ponikowski P, Kirwan B, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, and controlled trial. Lancet 2020; 396: 1895−1904. doi: 10.1016/S0140-6736(20)32339-4
    [64]
    Khan MS, Usman MS, von Haehling S, et al. Ferric carboxymaltose for the treatment of iron-deficient heart failure patients: a systematic review and meta-analysis. ESC Heart Fail 2020; 7: 3392−3400. doi: 10.1002/ehf2.13146
    [65]
    Lam PH, Taffet GE, Ahmed A, et al. Cardiac resynchronization therapy in older adults with heart failure. Heart Fail Clin 2017; 13: 581−587. doi: 10.1016/j.hfc.2017.02.011
    [66]
    Penn J, Goldenberg IA, Moss J, et al. Improved outcome with preventive cardiac resynchronization therapy in the elderly: A MADIT-CRT substudy. J Cardiovasc Electrophysiol 2011; 22: 892−897. doi: 10.1111/j.1540-8167.2011.02011.x
    [67]
    Kron J, Aranda JM., Miles W, et al. Benefit of cardiac resynchronization in elderly patients: Results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) trials. J Interv Card Electrophysiol 2009; 25: 91−96. doi: 10.1007/s10840-008-9330-2
    [68]
    Brambatti M, Guerra F, Matassini MV, et al. Cardiac resynchronization therapy improves ejection fraction and cardiac remodelling regardless of patients’ age. Europace 2013; 15: 704−710. doi: 10.1093/europace/eus376
    [69]
    Santangeli P, Di Biase L, Dello Russo A, et al. Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators. Ann Intern Med 2010; 153: 592−599. doi: 10.7326/0003-4819-153-9-201011020-00009
    [70]
    Kong M, Al-Khatib SM, Sanders GD, et al. Use of implantable cardioverter-defibrillators for primary prevention in older patients: A systematic literature review and meta-analysis. Cardiol J 2011: 503−514.
    [71]
    Køber L, Thune JL, Nielsen JC, et al. Defibrillator implantation in patients with non-ischemic systolic heart failure. N Engl J Med 2016; 375: 1221−1230. doi: 10.1056/NEJMoa1608029
    [72]
    Azad N, Lemay G. Management of chronic heart failure in the older population. J Geriatr Cardiol 2014; 11: 329−337.
    [73]
    Guerra F, Brambatti M, Matassini MV, et al. Current therapeutic options for heart failure in elderly patients. Biomed Res Int 2017: 1483873.
    [74]
    Sorabella RA, Yerebakan H, Walters R, et al. Comparison of outcomes after heart replacement therapy in patients over 65 years old. Ann Thorac Surg 2015; 99: 582−588. doi: 10.1016/j.athoracsur.2014.08.044
    [75]
    Rosenbaum N, John R, Liao K, et al. Survival in elderly patients supported with continuous flow left ventricular assist device as bridge to transplantation or destination therapy. J Card Fail 2014; 20: 161−167. doi: 10.1016/j.cardfail.2013.12.015
    [76]
    Kim JH, Singh R, Pagani FD, et al. Ventricular assist device therapy in older patients with heart failure: characteristics and outcomes. J Card Fail 2016; 22: 981−987. doi: 10.1016/j.cardfail.2016.10.004
    [77]
    Atluri P, Goldstone AB, Kobrin M, et al. Ventricular assist device implant in the elderly is associated with increased, but respectable risk: A multi-institutional study. Ann Thorac Surg 2013; 96: 141−147. doi: 10.1016/j.athoracsur.2013.04.010
    [78]
    Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res 2019; 124: 1598−1617. doi: 10.1161/CIRCRESAHA.119.313572
    [79]
    Beldhuis IE, Myhre PL, Bristow M, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383−1392. doi: 10.1056/NEJMoa1313731
    [80]
    Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. Circulation 2017; 136: e137−e161.
    [81]
    Solomon SD, McMurray J, Anand I, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019; 381: 1609−1620. doi: 10.1056/NEJMoa1908655
    [82]
    Adamson, P. B, Abraham W, Bourge R, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail 2014; 7: 935−944. doi: 10.1161/CIRCHEARTFAILURE.113.001229
    [83]
    Díez-Villanueva P, Ariza-Sole A, Vidan MT, et al. Recommendations of the Geriatric Cardiology Section of the Spanish Society of Cardiology for the assessment of frailty in the elderly patients with heart disease. Rev Esp Cardiol 2019; 72: 63−71. doi: 10.1016/j.recesp.2018.06.015
    [84]
    Vidan MT, Sanchez E, Fernandez-Aviles F, et al. FRAIL-HF, a study to evaluate the clinical complexity of heart failure in nondependent older patients: rationale, methods and baseline characteristics. Clin Cardiol 2014; 37: 725−732. doi: 10.1002/clc.22345
    [85]
    Yang X, Lupón J, Vidán MT, et al. Impact of frailty on mortality and hospitalization in chronic heart failure: a systematic review and meta-analysis. J Am Heart Assoc 2018; 7: e008251.
    [86]
    Martín-Sánchez FJ, Rodríguez-Adrada E, Vidán MT, et al. Impact of geriatric assessment variables on 30-day mortality among older patients with acute heart failure. Emergencias 2018; 30: 149−155.
    [87]
    Martín-Sánchez FJ, Llopis García G, Llorens P, et al. Planning to reduce 30-day adverse events after discharge of frail elderly patients with acute heart failure: design and rationale for the DEED FRAIL-AHF trial. Emergencias 2019; 31: 27−35.
    [88]
    Díez-Villanueva P, Salamanca J, Ariza-Solé A, et al. [Impact of frailty and other geriatric syndromes on the clinical management and prognosis of elderly ambulatory patients with heart failure. A prospective and multicentre study. Rev Esp Geriatr Gerontol 2020; 55: 29−33. doi: 10.1016/j.regg.2019.08.005
    [89]
    Lin H, Zhang H, Lin Z, et al. Review of nutritional screening and assessment tools and clinical outcomes in heart failure. Heart Fail Rev 2016; 21: 549−565. doi: 10.1007/s10741-016-9540-0
    [90]
    Sze S, Pellicori P, Kazmi S, et al. Prevalence and prognostic significance of malnutrition using 3 scoring systems among outpatients with heart failure: a comparison with body mass index. JACC Heart Fail 2018; 6: 476−486. doi: 10.1016/j.jchf.2018.02.018
    [91]
    Sze S, Zhang J, Pellicori P, et al. Prognostic value of simple frailty and malnutrition screening tools in patients with acute heart failure due to left ventricular systolic dysfunction. Clin Res Cardiol 2017; 106: 533−541. doi: 10.1007/s00392-017-1082-5
    [92]
    Cederholm T, Jensen GL, Correia MITD, et al. GLIM criteria for the diagnosis of malnutrition-A consensus report from the global clinical nutrition community. J Cachexia Sarcopenia Muscle 2019; 10: 207−217. doi: 10.1002/jcsm.12383
    [93]
    Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet 2019; 393: 2636−2646. doi: 10.1016/S0140-6736(19)31138-9
    [94]
    Landi F, Calvani R, Cesari M, et al. Sarcopenia as the biological substrate of physical frailty. Clin Geriatr Med 2015; 31: 367−374. doi: 10.1016/j.cger.2015.04.005
    [95]
    Haehling S. Muscle wasting and sarcopenia in heart failure: a brief overview of the current literature. ESC Heart Fail 2018; 5: 1074−1082. doi: 10.1002/ehf2.12388
    [96]
    Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019; 48: 16−31. doi: 10.1093/ageing/afy169
    [97]
    Lozano-Montoya I, Correa-Pérez A, Abraha I, et al. Nonpharmacological interventions to treat physical frailty and sarcopenia in older patients: a systematic overview. The SENATOR Project ONTOP Series. Clin Interv Aging 2017; 12: 721−740. doi: 10.2147/CIA.S132496
    [98]
    Junger J, Schellberg D, Muller-Tasch T. Depression increasingly predicts mortality in congestive heart failure. Eur J Heart Fail 2005; 7: 261−267. doi: 10.1016/j.ejheart.2004.05.011
    [99]
    Riegel B, Jaarsma T, Stromberg A. A middle-range theory of self-care of chronic illness. ANS Adv Nurs Sci 2012; 35: 194−204. doi: 10.1097/ANS.0b013e318261b1ba
    [100]
    Vidan MT, Martín Sánchez FJ, Sánchez E, et al. Most elderly patients hospitalized for heart failure lack the abilities needed to perform the tasks required for self-care: impact on outcomes. Eur J Heart Fail 2019; 21: 1434−1442. doi: 10.1002/ejhf.1559
    [101]
    Jaarsma T, Hill L, Bayes-Genis A, et al. Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2020; 23: 157−174.
    [102]
    Krishnaswami A, Beavers C, Dorsch MP, et al. Gerotechnology for Older Adults With Cardiovascular Diseases: JACC State-of-the-Art Review. J Am Coll Cardiol 2020; 76: 2650−2670. doi: 10.1016/j.jacc.2020.09.606
    [103]
    Bonanad C, García-Blas S, Tarazona-Santabalbina FJ, et al. The contributing authors are members of the following scientific bodies. Coronavirus: the geriatric emergency of 2020. Joint document of the Section on Geriatric Cardiology of the Spanish Society of Cardiology and the Spanish Society of Geriatrics and Gerontology. Rev Esp Cardiol (Engl Ed) 2020; 73: 569−576. doi: 10.1016/j.recesp.2020.03.027
    [104]
    Díez-Villanueva P, Bonanad C, Ariza-Solé A, et al. Telematic cardiology consultation in the elderly. The 5M framework can help. Rev Esp Cardiol (Engl Ed) 2021; 74: 116−117.
    [105]
    Jaarsma T, Beattie J, Ryder M, et al. Palliative care in heart failure: A position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009; 11: 433−443. doi: 10.1093/eurjhf/hfp041
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(5)

    Article Metrics

    Article views (29) PDF downloads(8) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return